Coronary (atherosclerosis or artery disease) or triple vessel disease of the heart

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Presence of MSIMI was associated with 21% and 20% slower completion of Trail-A and Trail-B respectively in patients with stable coronary atherosclerosis, after adjustment for demographics, clinical ri

Effect: decline; B 0.21 (Trail-A); B 0.20 (Trail-B)

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null

Conventional stress-induced myocardial ischemia (CSIMI) was not associated with any cognitive function measures at baseline or with cognitive decline over 2-year follow-up in patients with stable coro

Effect: null